Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd. Chief Executive Officer Timothy Mark Dyer filed an initial insider ownership report. He reports direct ownership of 16,848,979 shares of common stock listed on SIX Swiss Exchange. This filing does not show new purchases or sales; it establishes his existing position.
Dyer also holds stock options giving the right to buy 3,369,796 shares of common stock at an exercise price of $0.064 per share. These options vest in equal monthly installments over four years starting on the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars based on a stated CHF-to-USD exchange rate as of March 12, 2026.
Addex Therapeutics Ltd. director Jason Raleigh Nunn filed an initial ownership report showing his existing stake in the company. He directly holds 219,561 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 50,000 shares of Common Stock.
The stock options have an exercise price of $0.0640 per share, become exercisable in equal monthly installments over a four-year period beginning on the exercise start date of January 8, 2024, and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a stated CHF-to-USD exchange rate.
Addex Therapeutics director Isaac Manke reported his initial holdings. He directly owns 219,561 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options on 50,000 shares of Common Stock with a $0.064 exercise price.
The stock options began vesting in equal monthly installments over a four-year period starting on January 8, 2024 and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a CHF-to-USD exchange rate as of March 12, 2026.
Addex Therapeutics furnished a report detailing new preclinical data supporting its mGlu7 negative allosteric modulators as a potential treatment for anxiety and fear-related disorders. The data, published in Molecular Psychiatry, focus on ADX71743, a highly selective mGlu7 modulator.
In rat models of fear learning and memory, ADX71743 disrupted fear memory reconsolidation after recall, reducing reinstatement of fear and acting within a defined time window. Electrophysiology showed modulation of glutamatergic transmission at thalamus-to-amygdala synapses, with similar synaptic effects observed in human brain tissue, providing early translational support.
The company emphasizes mGlu7 as a promising target for conditions such as PTSD, OCD, anxiety, depression, drug abuse and schizophrenia, and notes its broader allosteric modulator portfolio, including dipraglurant for brain injury recovery and partnered and spin-out programs in GABAB, M4 and mGlu7.
Addex Therapeutics furnished a report highlighting progress at its spin-out company Neurosterix, which has started a Phase 1 clinical study of NTX-253, an oral positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia. The first-in-human trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Neurosterix was spun out of Addex in April 2024 and raised $65 million in a Series A financing led by funds affiliated with Perceptive Advisors; Addex retains a 20% equity interest in the company. The filing also reiterates Addex’s broader neurology-focused pipeline, including lead candidate dipraglurant for brain injury recovery, partnered and independent GABAB PAM programs for substance use disorders and chronic cough, and its investments in Neurosterix and Stalicla.
Addex Therapeutics Ltd has filed a shelf registration on Form F-3 to offer up to $150,000,000 of ordinary shares, which may be issued directly or as American Depositary Shares, each ADS representing 120 ordinary shares. The securities may be sold over time in one or more primary offerings using various methods, including underwriters, dealers, agents or direct sales, with specific terms to be detailed in future prospectus supplements.
The ADSs trade on Nasdaq under “ADXN” and the shares trade on SIX under “ADXN.” As of November 17, 2025, the ADS price on Nasdaq was $8.47, and the SIX share price was CHF 0.0572 (approximately $0.072 per share, or about $8.64 per ADS). Under Form F-3 General Instruction I.B.5, Addex may not sell more than one‑third of its $9.05 million public float in primary offerings in any 12‑month period.
Addex Therapeutics (ADXN) furnished a Form 6-K noting it issued a press release on October 29, 2025, attached as Exhibit 99.1 and incorporated by reference.
The press release is deemed part of Addex’s registration statements on Form F-3 (No. 333-255089) and Form S-8 (Nos. 333-255124 and 333-272515) from the filing date, unless later superseded.
Addex Therapeutics Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish its unaudited interim condensed consolidated financial statements and related commentary for the periods ended June 30, 2025. The filing includes financial statements, management’s discussion and analysis of financial condition and results of operations, and a press release dated September 30, 2025.
The company states that Exhibits 99.1 and 99.2 are incorporated by reference into its existing shelf registration on Form F-3 and its Form S-8 registration statements, meaning these updated interim figures and discussions now form part of those registration documents. The report reiterates that Addex faces significant risks described in its prior Form 20-F and that forward-looking statements are subject to those risks.
Addex Therapeutics Ltd furnished a Form 6-K as a foreign private issuer for September 2025. The company reports that on September 23, 2025 it issued a press release, attached as Exhibit 99.1. The press release is incorporated by reference into its existing Form F-3 and Form S-8 registration statements.
Addex Therapeutics Ltd furnished a Form 6-K as a foreign private issuer for September 2025. The company reports that on September 23, 2025 it issued a press release, attached as Exhibit 99.1. The press release is incorporated by reference into its existing Form F-3 and Form S-8 registration statements.